Inbrija (Levodopa) Patent Expiration, LOE Window & CMS Spending

Inbrija (Levodopa) by Merz: FDA Orange Book LOE 2033-10-21, 0 AB generics, $29.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerz
FDA Application & PathwayN209184 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-10-21
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$29.1M
2024 Medicare Part D Spend$27.7M
2024 Medicaid Spend$1.4M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 22.4% 2-yr change)